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Novel insights into vascularization patterns and angiogenic 
factors in glioblastoma subclasses
Siobhan Co roy1 · Michiel Wagemakers2 · Annemiek M. E. Walenkamp3 ·  
Frank A. E.Kruyt3 · Wilfred F. A. den Dunnen1
deposition and pericyte coverage did not vary between 
the subtypes. Regarding signaling patterns the majority of 
factors were expressed at similar levels in the subtypes, 
and only ANGPT2, MMP2, TIMP1, VEGFA and MMP9/
TIMP2 were higher expressed in GBMs of the classical-
like subtype. In conclusion, although morphological differ-
ences were observed between the subtypes, the angiogenic 
signaling status of GBM subtypes seemed to be rather sim-
ilar. These results challenge the concept of mesenchymal 
GBMs being more angiogenic than other subclasses.
Keywords Angiogenesis · Glioblastoma · Subcl sses · 
Subtypes
Introduction
Glioblastoma (GBM) is the most common primary brain 
tumor and is among the most vascularized solid tumors 
[1–4]. The dismal prognosis of patients with GBM warrants 
development of more effective therapies. Despite the gen-
ral consensus that GBM comprises a tumor with extensive 
heterogeneity, all patients are currently still treated uni-
formly [2, 5, 6].
Molecular subclasses have been described over the past 
decade based on gene expression patterns, but the discus-
sion on the exact number of subclasses is still ongoing. Ini-
tially a set of three subclasses was identified [7], but the 
definition was strongly refined, expanded to four subclasses 
and specific molecular aberrations were coupled to the sub-
classes by The Cancer Genome Atlas (TCGA) Network [8]. 
The discussion is still not definite and only recently another 
proposition for subgroups of gliomas has been postulated 
[9]. From the earlier profiling endeavors, however, three 
molecular subclasses can be distilled consistently which 
Abstract Glioblastoma (GBM) is a highly vasculariz d 
and aggressive type of primary brain tumor in a ults with 
dismal survival. Molecular subtype  of GBM have be n 
identified that are related to clinical outcome and response 
to therapy. Although the mesenchymal type has been 
ascribed higher angiogenic activity, extensive character-
ization of the vascular compon nt in GBM subtypes has 
not been performed. Therefore, we a med o investigate th  
differential vascular status nd angiogenic signaling l vels 
in molecular subtypes. GBM tissue samples represent ng 
proneural IDH1 mutant, classical-like and mesenchymal-
like subtypes were analyzed by morphometry f r the num-
ber of vessels, vessel size and vessel maturity. Also the 
expression levels of factors from multiple angiogenic sig-
naling pathways were determined. We found that necrotic 
and hypoxic areas were relatively larger in mesenchymal-
like tumors and these tumors also had larger vessels. 
However, the number of vessels, b ement membrane 
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IDH1mut, CLAS-like and MES-like where the analyses con-
cern these tumors. Archival tissue of all patients was han-
dled according to the Dutch Code of Conduct for proper 
secondary use of human tissue (http://www.fed ra.org).
Level 3 gene expression data was obtained of 146 GBM 
patients that were previously transcriptionally subclassified 
(core TCGA samples, http://cancergenome.nih.gov/) [8]. 
The age at diagnosis in this cohort was 55 and the male per-
centage was 62. Clinical characteristics of both cohorts are 
summarized in Table 1.
Necrosis measurement on MRI scans
Pre-operative imaging of the Groningen cohort was used to 
measure the volume of central necrosis in relation to total 
tumor volume. Volume contrast-enhanced T1 MRIs suit-
able for volume measurements were available for 24 of 
30 patients. Amongst the 6 patients lacking a scan of suf-
ficient quality, there were 3 PN IDH1mut, 2 CLAS-like and 
1 MES-like tumor. The scans were analyzed three-dimen-
sionally in Brainlab iPlan® Cranial planning software ver-
sion 3.0 (Brainlab AG, Feldkirchen, Germany), on which 
the enhanced area was interpreted as vital tumor, and the 
non-enhanced central area of the tumor as necrosis. As a 
measurement for total tumor area the enhanced and the non-
enhanced central area were added up.
IHC procedure
Sections were cut from FFPE tissue in series and IHC stain-
ing was performed as described previously [18 ]. Sections 
were stained for Carbonic anhydrase IX (CAIX), CD34, 
Endoglin (ENG), collagen type IV alpha 1 (ColIV) and 
α-smooth muscle actin (α-SMA).
Morphometrical analyses
The microvascular density (MVD) was microscopically 
assessed using the Chalkley grid. The average number of 
vessels per mm2, average vessel area and vessel perimeter 
were determined using computer-assisted morphometry.
include the proneural (PN), classica  (CLAS)  mesen-
chymal (MES) subclasses.
Thus far only few studies hav  reported on the angio-
genic properties of the molecular subclasses. Platelet/
endothelial cell adhesion molecule 1 (PECAM1), vascular
endothelial growth factor A (VEGFA) nd vascular endo-
thelial growth factor receptor 1 and 2 (VEGFR1, 2) were 
reported to be upregulated in MES GBMs [7]. O her results 
only have described differential r sponses of GBMs to anti-
angiogenic treatment in both the pre-clinical and clinical 
setting. One study has addressed whether the differences in 
response were associated with the molecula  subclasses and 
reported selected benefit for PN subclass [10]. In an aor-
tic ring assay anti-VEGFA treatment abrogated microves-
sel sprouting in one cell lin  but no  in the other [11 ], and 
tumor recurrences following anti-VEGFA treatment could 
be divided in distinct resistance phen typ s [12 ].
Since the subclasses are char ct rized by molecular 
aberrations, differential employment of angiogenic signal-
ing pathways could also be suggested based on the defining 
features of the subclasses. It has for example been shown 
that IDH1mutant protein, which is exclusively expressed in 
PN GBMs, stabilizes HIF-1α-expression [13 ]. HIF-1α on its 
turn is known as a potent inducer of giogenesis via mul-
tiple signaling pathways [14]. The expre sion of EGFRvIII, 
the constitutively active (mutant) form of EGFR character-
istic of CLAS GBMs, was on the other hand reported to 
promote angiogenesis by activating the IL-8 pathway and 
inducing expression of cytokines and interleukins [15 , 16].
To determine whether specific angiogenesis-related fac-
tors could serve as possible ew candidates for GBM sub-
class-differentiated anti-angiogenic therapy, we assessed 
the vascular status of the subclasses using morphometry, 




Tissue samples from 30 patients diagnosed with GBM were 
selected for the Groningen cohort. All patients underwent 
neurosurgical debulking at the University Medical Center 
Groningen (UMCG) in the Netherlands in the period August 
2006 to May 2012. The mean age at diagnosis was 55 and 
the higher incidence rate in males was reflected in the male 
to female ratio (67 % m le) [17 ]. The samples selected for 
this study, 10 per subclass, were all previously identified as 
PN (IDH1mut), CLAS-like and MES-like subclasses [18 ]. 
Due to the fact that this cohort of GBMs was not subclas-
sified transcriptionally but instead through a protein-based 
approach, we refer to the subclasses of these tumors as PN 
Table 1 Summary of characteristics of patients with GBM in the 





Number of patients30 146
Mean age at diagnosis (95 % CI) 55 (49–60) 55 (53–58)
Median overall survival in days  
(range)
526 (62–1447) 361 (0–3524)
Male sex (%) 20 (67) 91 (62)
Female sex (%) 10 (33) 55 (38)
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subclasses [7, 8]. Kaplan–Meier analysis revealed that the 
survival of PN IDH1mut, CLAS-like and MES-like subclasses 
differed (P < 0.05, Log-rank test, Online Resource 2) similar 
to the originally identified molecular subclasses [7, 8].
Hypoxic and necrotic tissue areas are more prevalent in 
MES-like GBMs
The MES subclass has been considered the most angiogenic 
subclass that also displays a higher level of necrosis [21 ]. 
Since hypoxia is known to be a potent inducer of neo-angio-
genesis and areas of hypoxia often surround necrotic tissue 
[22 , 23 ], we determined the size of necrotic and hypoxic 
tissue on pre-operative MRIs and in biopsied tissue speci-
mens, respectively.
The volume of central necrosis and total tumor volume 
were calculated in 3D, for which central non-enhanced areas 
were interpreted as necrosis and volumetrically compared to 
the contrast-enhanced total tumor size (Fig. 1a). These mea-
surements pointed out that the volume of necrotic tissue was 
correlated with total tumor volume (SR = 0.824, P < 0.01, 
Fig. 1b), illustrating that larger tumors tend to have more 
necrosis. Since PN IDH1mut tumors appeared smaller on the 
scans (but not significantly), the level of necrosis needed 
to be corrected for total tumor volume. The percentage of 
necrosis, when expressed against the total tumor volume, 
still showed a trend for a lower level of necrosis in PN 
IDH1mut tumors (Fig. 1c).
The level of hypoxia was assessed through CAIX on tis-
sue sections, a marker known to be suitable for the identifica-
tion of tumor hypoxia [24]. Staining for CAIX was observed 
in only a fraction of the vital tissue area and could indeed 
be observed around necrosis (Fig. 1d). The stainin  for 
CAIX was significantly enriched in the tissue areas that were 
selected as hypoxic (all Pvalues < 0.001, Online Resource 
3). Of the GBM subclasses the MES-like group appeared to 
have relatively the largest hypoxic area (Fig.1e).
In order to connect the necrosis and hypoxia measure-
ments the correlation was determined, which identified an 
association between the parameters (SR = 0.4838, P < 0.05, 
Fig. 1 f). Although the association is already significant as 
it is, it is conceivable that it would be stronger if the per-
centage of hypoxic tissue would be a little higher. It is very 
likely that the level of hypoxia in our analyses did underes-
timate the true level of hypoxia, as our tissue samples were 
obtained from vital tumor areas to be most suitable for diag-
nostic procedures.
Endothelial marker expression and MVD in GBM 
subclasses
Then the expression of endothelial markers CD34 (Fig. 2a) 
and neo-endothelial marker ENG (Fig. 2d) was assessed in 
Histological evaluation
The expression levels of CAIX, CD34, ENG, ColIV and 
α-SMA were quantified using Aperio ImageScope software. 
Vital tumor tissue was delineated on every individual sec-
tion and staining, and hypoxic tissue was delinea ed using 
the CAIX staining pattern as guidanc . The positive pixel 
percentage was calculated by division of the surface area 
found positive (in pixels) by the total rea of th  vital, no-
moxic or hypoxic field (in pixels), a method previously 
applied by others [19,20]. Since staining for α-SMA and 
ColIV was specifically identified around vessels, an indi-
cation of the thickness of these layers was obtained by 
dividing the number of positive pixels by th  total vessel
perimeter of that sample.
Microfluidic cards
RNA was purified from 30 snap-frozen GBM biopsy sam-
ples and reverse transcribed to cDNA. Custom-designed 
Taqman array Micro Fluidic Cards (low-density array, 
Applied Biosystems, Foster City, CA  were used o ob ain
gene expression analyses of these samples by analysis on a 
ViiA™ 7 real-time sequence detection system (Applied Bio-
systems). Assays were included for 31 genes of interest and 
one endogenous control.
Statistical analysis
Statistical analyses were performed usi g SPSS software 
version 22.0 (SPSS, Chicago, IL) and visualized us g 
Graphpad Prism version 5 (Graphpad Software Inc, San 
Diego, CA). Correlations were calculated by Spearman’s 
rho (SR). Normal distributions were tested by on -way 
ANOVA or t test and data not norma ly distribut d was 
tested by a Kruskal–Wallis test or Mann–Whitney U test. 
The multiple group comparisons were followed up by either 
Tukey’s or Dunn’s post-hoc tests. P values < 0.05 were co-
sidered significant and in all cases exact two-sided P values 
were reported.
Supplementary Methods can be found online (Online 
Resource 1).
Results
PN IDH1mut tumors have a better pr gnosis than MES-
like tumors
The probability of overall rvival (OS) was assessed to 
determine whether IHC-based molecular stratification iden-
tified subclasses with similar survival periods as those that 
were initially reported for the transcription-based molecular 
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as we had observed differences in MVD-values between 
the subclasses, we decided to correct for the endothelial 
lining of the vessels. The positive pixel count was there-
fore divided by the total vascular perimeter measurement. 
By doing so, the trend for lower ColIV expression in PN 
IDH1mut tumors was not maintained (Fig.3d). The trend for 
increased α-SMA expression in MES-like tumors was still 
visible, but a little less clear (Fig. 3h). The comparison of 
hypoxic and normoxic tissue did not report differences in 
vascular maturation status between the subclasses (Online 
Resource 5).
Angiogenic signaling pathway upregulation is not 
associated with GBM subclasses
Finally, to assess whether angiogenic signaling was differ-
ent in molecular subclasses of GBM the expression levels 
of several angiogenic signaling factors was quantified. The 
most important angiogenic functions of the specific signal-
ing molecules are summarized in Online Resource 6.
Out of the 31 assessed factors, only 4 were differentially 
expressed in the subclasses. The pro-angiogenic factors 
angiopoietin-2 (ANGPT2) and vascular endothelial growth 
factor A (VEGFA) were found to be expressed at a higher 
level by CLAS-like tumors (Fig. 4a, b). In addition to these 
pro-angiogenic factors, the expression of matrix metallopro-
teinase 2 (MMP2) was also elevated in CLAS-like tumors 
(Fig. 4c). However, its endogenous inhibitor, tissue inhibi-
tor of metallopeptidase 1 (TIMP1), was also upregulated in 
CLAS-like tumors (Fig. 4e).
When the expression of the MMPs was related to the 
expression of their corresponding endogenous inhibitors 
(TIMPs), it appeared that while MMP2 was differentially 
expressed at an absolute level, the corrected expression ratio 
MMP2/TIMP1 did not differ between the molecular sub-
types (Fig. 4g). On the contrary, uncorrected MMP9 was not 
differentially expressed (Fig. 4d), but th  MMP9/TIMP2 
ratio was different between the subclasses with the highest 
level observed for CLAS-like GBMs (Fig. 4h).
In Fig. 4i the differential expression of the assessed 
angiogenic targets in molecular subclasses is depicted in a 
Venn diagram. It can be appreciated that the molecular sub-
classes of GBM have highly similar expression patterns of 
angiogenic factors.
Discussion
Because of the highly vascularized nature of GBMs we 
hypothesized that anti-angiogenic therapy could have 
an effect in these tumors. The novel therapeutics that 
seemed promising in pre-clinical studies, unfortunately, 
only rarely produced similar results in clinical trials. For 
order to analyze the vascularizati n patte ns. The mRNA 
expression level in the Verhaak cohort indi ated that CD34 
and ENG are upregulated in MES tumors i  comparison 
to PN tumors (Fig. 2b, e). At protein level th  relativ
expression of CD34 was however not di ferent between the 
molecular subclasses (Fig. 2c). Similarly, no differences in 
relative protein expression of ENG were observed either 
(Fig. 2f). Using the staining pattern for CAIX as guidance, 
we then assessed whether the xpression differed between 
normoxic and hypoxic tissue a eas. Also i  this subdivision 
of the tissue the expression of endothelial m rkers remained 
similar in all subclasses (Online Resource 4).
The vascularization pattern analysis was then continued 
by the assessment of multiple MVD-parameters. A Chalkley 
grid evaluation pointed out that MES-lik  tumor  have larger 
vessels than PN IDH1mut tumors (Fig. 2g, P< 0.05). Th  
average vessel area and vessel per meter were also found
to be larger in MES-like tumors (Fig. 2i, j, P < 0.01), but the 
number of vessels was not different between the su classes 
(Fig. 2h). Between normoxic and hypoxic tissue areas only
CLAS-like tumors were found to have more vessels in the 
hypoxic areas (P < 0.001), and no differences were observed 
for the other MVD-parameters (Online Resource 4).
Vessels of molecular subclasses ar  not different in 
maturation status
The vascular maturation status of PN IDH1mut, CLAS-like 
and MES-like GBMs was then assessed by IHC analyses 
for the expression of the basement membrane marker ColIV 
(Fig. 3a) and pericyte coverage of vessels was assessed by 
staining for α-SMA (Fig. 3e). The mRNA expression of 
these markers in the Verhaak cohort [8] indic ted a l wer 
expression level of COL4A1 in PN tumors (F g. 3b), and 
an increased expression level o  ACTA2 in MES tumors 
(Fig. 3f). At protein level we observed similar patterns in the 
Groningen cohort by IHC analyses (Fig. 3c, g). However, 
Fig. 1 The rate of necrosis is associ ted with total tumor volume and 
MES-like tumors have a relatively higher percentage of hypoxic tumor 
area. Pre-operative radiographic scans of patients were analyzed for 
the volume of necrosis and total tumor, in which the total tumor area 
(right image) and the central necrosis (middle im ge) were delineated 
(a). The volume of necrosis was found to gradually increase with total 
tumor volume (SR = 0.824, P < 0.01) (b), but the percentage of necro-
sis only showed a trend for a lower level of necrosis in PN IDH1mut 
GBMs (c). A representative micrograph of CAIX stain g is shown 
(d), where ‘N’ indicates necrotic tissue, and the arrowheads indicat  
staining for CAIX. A rim surrounding the necrosis is depicted hat was 
positive for CAIX expression. Quantification of these positive CAIX 
sites and comparing them against total vital tumor area indicated that 
the percentage of hypoxic tissue is higher in MES-like GBMs com-
pared to CLAS-like GBMs (e). The percentage of hypoxic tumor area 
was found to be associated with the proport on of necrosis measured 
on the MRIs (SR = 0.4838, P < 0.05) (f). Horizontal lines represent 
median score of the groups; scale bar 250 µm; *P < 0.05

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In agreement with previous reports, we found that MES-
like tumors are enriched for necrosis [21 ]. As it is known 
that necrotic tissue is often surrounded by hypoxic areas 
[22 ], and hypoxia is a potent inducer of angiogenesis, high 
angiogenic potential was expected from MES tumors. 
By performing extensive characterization of the vascula-
ture we were able to establish that MES-like tumors have 
larger, but not more vessels than other subclasses. This con-
tradicted our hypotheses, since active angiogenesis would 
likely have resulted in predominantly small, newly formed 
vessels. Previous studies have however shown that larger 
vessels do not necessarily indicate better oxygenation, as 
the oxygenation status is more dependent on blood flow 
rate and diffusion distance from the vessel to the cells [28 ]. 
example Bevacizumab, a promising anti-angiogenic dr g 
in the pre-clinical setting, only resulted in an impr ve-
ment of progression-free survival and left th overall 
survival of patients unaltered in two large Phase 3 ran-
domized clinical trials when it was added o s andard che-
motherapy for newly diagnosed GBM patie ts [25 , 26]. 
A slight improvement in overall survival was observed 
for Bevacizumab addition to chemotherapy (Lomustine) 
for recurrent GBM patients [27 ], but it is evident that 
more extensive research is needed to identify patients that 
could potentially benefit from these types of treatments. 
Therefore, in this study we aimed to identify vascu ar 
abnormalities specific of the PN IDH1mut, CLAS-like and 
MES-like subclasses of GBM.
Fig. 2 Endothelial marker expression is increased in MES-like GBMs 
that on average have larger vessels. The expression patterns of endo-
thelial marker CD34 () and neo-endothelial marker ENG (d) is owest 
in PN IDH1mut tumors and highest in MES tumors at mRNA level (b, 
e). When this is evaluated at protein level, the differences between the 
subclasses do not maintain for CD34 expression (c), but a trend can 
still b  observed for elevated expression of ENG in MES-like tumors 
(f). Morphometric assessm nt  of vessels, including Chalkley grid 
score (a), average vessel area (c), and vessel perimeter (d) showed hat 
MES-like GBMs ha  larger vessels than PN IDH1mut GBMs, but the 
number of vessels per mm2 (b) did not differ. Horizontal lines epr sent 
medi values; cal  bar 50µm; *P < 0.05, **P < 0.01, ***P < 0.001
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We believe that although the corrections for the number of 
vessels and vessel perimeter introduced differences between 
the mRNA and protein analyses, they can provide very 
useful information. It was due to these corrections that we 
were able to elucidate that the increased expression level of 
basement membrane and pericyte markers could actually be 
explained by an increase of vascular size.
The current study did not reveal an association between 
the angiogenic signaling network and GBM subclasses. 
As outlined earlier, genetic aberrations linked to particu-
lar molecular subclasses were presumed to affect different 
angiogenic downstream targets, however the expression of 
these targets appeared not to be different between the sub-
classes. Surprisingly, the few upregulated angiogenic tar-
gets were actually highest in CLAS-like and not MES-like 
tumors.
Given the scarceness of pre-clinical data it is interesting that 
a clinical trial with anti-angiogenic therapy (Bevacizumab) 
has included an analysis for the molecular subtypes. In this 
trial standard of care was supplemented with Bevacizumab 
(anti-VEGFA treatment) and especially the IDH1 wild-type 
PN tumors benefited from the addition of Bevacizumab [10]. 
Since our selection of PN tumors was based on an IDH1 muta-
tion, we were unable to address this subset of PN tumors.
In conclusion, we report that although MES-like 
GBMs have larger vessels and PN IDH1mut tumors tend to 
Therefore, an increased flow rate in these tumors could still 
have resulted in a lower oxygenation level in MES-l k  
tumors. Reduced perfusion in the MES-like tumors thus 
provides a potential connection between the larger vess l 
size in this subclass and the increased rate of necrosis and 
hypoxia. In this regard it would b  int resting to analyze 
vaso-occlusive events in GBM, which itself has a profound 
effect on blood flow and oxygenation of target tissues [29].
Furthermore, neo-angiogenesis could also be reflected 
by a more abundant expression of endothelial mark rs and 
a lower maturation rate of vessels. These hypotheses were 
partly confirmed by the data from the TCGA data reposi-
tory, as those indicated elevated expr s ion lev ls f endo-
thelial markers CD34 and ENG in MES tumors at the mRNA 
level. At the protein level we were unable to identify such 
differences. Against our expectation, we found that the ves-
sel maturity markers α-SMA and ColIV were elevated at 
mRNA level in the MES-like subcl ss comp red to the PN 
IDH1mut subclass, and a similar trend was also observed at 
protein level. Because we established through morphometry 
that MES-like tumors have larger vessels w  then applied a 
correction for vessel size. This correction led to f ding of the 
differences observed at protein level, implying that the ves-
sel size explained (part of) the differences in xpression and 
there is no true difference in basement membrane d sition 
or pericyte coverage around the vessels of GBM subc asses. 
Fig. 3 The vascular maturation status of GBM subclasses is rather 
similar. The mRNA expression of basement membrane marker 
ColIV (a) is highest in CLAS and MES GBMs (b). At protein level 
the expression of ColIV still shows a trend for higher expression in 
MES-like GBMs when corrected for total tissue area (c), but this rend 
disappears when the layer thickness of ColIV is determined through 
division of the positive pixels by the total vascular perimeter (d). For 
α-SMA (e) an increased mRNA expr ssion level was also observed for 
MES tu ors (f), but this remained a significant difference at protein 
lev l when we corrected for total tissue area (g). The correction for the 
total vascular perimeter eventually reduced the differenc s in α-SMA 
expression to a trend for elevated expression in MES-like tumors (h). 
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GBMs being more angiogenic. It can be presumed that 
the lack of correction in prior studies possibly has led to 
the erroneous expectation of increased angiogenic activ-
ity in the MES subclass. As such, our results do not sup-
port attempts to differentiate anti-angiogenic treatment 
according to the GBM molecular subtypes assessed in 
this study.
possess less necrosis and hypoxia, no major d ff rences 
in angiogenic signaling patterns were observed between 
GBM subclasses at the time of diagnosis. Although our 
study did not functionally address neo-angiogene is, by 
the use of vascularization at erns and signaling sign-
tures as a measure for the outcome of neo-angiogenic 
processes, our findings challenge the concept of MES 
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